Vaccines to Prevent Meningitis: Historical Perspectives and Future Directions

Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial

(2020) Judith Absalon et al.   LANCET INFECTIOUS DISEASES

Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial

(2020) Shabir A Madhi et al.   LANCET INFECTIOUS DISEASES

Vaccines against Meningococcal Diseases

(2020) Mariagrazia Pizza et al.   Microorganisms

Subdominance in Antibody Responses: Implications for Vaccine Development

(2020) Gunnar Lindahl   MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS

Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trials

(2019) Michael White et al.   LANCET INFECTIOUS DISEASES

Serocorrelates of protection against infant group B streptococcus disease

(2019) Kirsty Le Doare et al.   LANCET INFECTIOUS DISEASES

A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization

(2019) Ed T Buurman et al.   JOURNAL OF INFECTIOUS DISEASES

The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations

(2019) Johan Vekemans et al.   VACCINE

Outbreaks of meningococcal meningitis in non-African countries over the last 50 years: a systematic review

(2019) Femke van Kessel et al.   Journal of Global Health

Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study

(2019) S. M. Niaz Arifin et al.   MEDICAL DECISION MAKING

Vaccines for maternal immunization against Group B Streptococcus disease: WHO perspectives on case ascertainment and case definitions

(2019) Anna C. Seale et al.   VACCINE

A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB‐FHbp

(2019) Cynthia Burman et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Immunogenicity Comparison of a Next Generation Pneumococcal Conjugate Vaccine in Animal Models and Human Infants

(2019) Jinfu Xie et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia—Results of a phase 1/2 randomized, double-blinded, controlled trial

(2019) Ed Clarke et al.   VACCINE

Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial

(2018) David Goldblatt et al.   LANCET INFECTIOUS DISEASES

Temperature-Induced Self-Assembly of the Group B Streptococcus (GBS) Fusion Antigen GBS-NN

(2018) Fabrice Rose et al.   MOLECULAR PHARMACEUTICS

Lessons from the Meningitis Vaccine Project

(2018) F. Marc LaForce et al.   VIRAL IMMUNOLOGY

Glycoconjugate vaccines: Principles and mechanisms

(2018) Rino Rappuoli   Science Translational Medicine

Meningococcal B vaccine (4CMenB): the journey from research to real world experience

(2018) Rino Rappuoli et al.   Expert Review of Vaccines

Global, regional, and national burden of meningitis, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2018) Joseph Raymond Zunt et al.   LANCET NEUROLOGY

Protection Against Invasive Infections in Children Caused by Encapsulated Bacteria

(2018) Manish Sadarangani   Frontiers in Immunology

WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27–28 April 2016

(2016) Miwako Kobayashi et al.   VACCINE

Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso

(2015) Anaïs Colombini et al.   CLINICAL INFECTIOUS DISEASES

From Epidemic Meningitis Vaccines for Africa to the Meningitis Vaccine Project

(2015) M. Teresa Aguado et al.   CLINICAL INFECTIOUS DISEASES

Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010–2014

(2015) Mamoudou H. Djingarey et al.   CLINICAL INFECTIOUS DISEASES

Regulatory considerations in the clinical development of vaccines indicated for use during pregnancy

(2015) Jeffrey N. Roberts et al.   VACCINE

Survey of Immunological Features of the Alpha-Like Proteins of Streptococcus agalactiae

(2014) Johan A. Maeland et al.   Clinical and Vaccine Immunology

Use of vaccines as probes to define disease burden

(2014) Daniel R Feikin et al.   LANCET

Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study

(2014) Nick J Andrews et al.   LANCET INFECTIOUS DISEASES

Review of meningococcal vaccines with updates on immunization in adults

(2014) Yorgo C Zahlanie et al.   Human Vaccines & Immunotherapeutics

Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial

(2014) Miguel W. Tregnaghi et al.   PLOS MEDICINE

Prevention of Staphylococcus aureus Infections by Glycoprotein Vaccines Synthesized in Escherichia coli

(2013) Michael Wacker et al.   JOURNAL OF INFECTIOUS DISEASES

Progress towards Demonstrating the Impact of Haemophilus influenzae Type b Conjugate Vaccines Globally

(2013) Rana Hajjeh et al.   JOURNAL OF PEDIATRICS

Cost-Effectiveness of Haemophilus influenzae Type b Conjugate Vaccine in Low- and Middle-Income Countries: Regional Analysis and Assessment of Major Determinants

(2013) Ulla Kou Griffiths et al.   JOURNAL OF PEDIATRICS

Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity

(2013) F. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Advance market commitment for pneumococcal vaccines: putting theory into practice

(2012) Tania Cernuschi et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial

(2012) Arto A Palmu et al.   LANCET

Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2–10 years: A Phase II/III double-blind randomized controlled trial

(2012) Siddhivinayak Hirve et al.   VACCINE

Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans

(2011) Samba O. Sow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Accelerating introduction of new vaccines: barriers to introduction and lessons learned from the recent Haemophilus influenzae type b vaccine experience

(2011) R. Hajjeh   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Supporting new vaccine introduction decisions: Lessons learned from the Hib Initiative experience

(2010) R.A. Hajjeh et al.   VACCINE

Glycoconjugate vaccines and immune interference: A review

(2010) Ron Dagan et al.   VACCINE

Rethinking the benefits and costs of childhood vaccination: The example of the Haemophilus influenzae type b vaccine☆

(2010) Till Bärnighausen et al.   VACCINE

Dispute over pneumococcal vaccine initiative

(2009) Ann Danaiya Usher   LANCET

Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates

(2009) James P Watt et al.   LANCET

Worldwide introduction and coverage of Haemophilus influenzae type b conjugate vaccine

(2008) Rosalyn O'Loughlin et al.   LANCET INFECTIOUS DISEASES

The impact of vaccines on pneumonia: Key lessons from Haemophilus influenzae type b conjugate vaccines

(2008) Bradford D. Gessner et al.   VACCINE